Akebia: Is This A Potential Winner? [Seeking Alpha]
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Seeking Alpha
Akebia: Is This A Potential Winner? Summary The current bear market offers many high-quality companies that are on sales at a deep bargain. As we continue our bargain-hunting quest, we stumbled upon Akebia Therapeutics. The company recently completed its merger with Keryx Pharmaceuticals. Keryx’s approved medicine, Auryxia, provides increasing cash flow to help Akebia fund further pipeline innovation. We’ll assess whether Akebia will post positive clinical data its lead drug Vadadustat and whether it has good market potential. With every new wave of optimism or pessimism, we are ready to abandon history and time-tested principles, but we cling tenaciously and unquestioningly to our prejudices. - Benjamin Graham Back on Dec. 13, 2018, Keryx Pharmaceuticals and Akebia Therapeutics (NASDAQ: AKBA announced initially approved additional approval Figure 1: Akebia chart. (Source: StockCharts Fundamental Headquartered in Cambridge, Massachusetts, the newly-merged company (Akebia) is powering
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia [Yahoo! Finance]Yahoo! Finance
- CNN values your feedback [CNN]CNN
- Thinking about buying stock in Ocugen, Akebia Therapeutics, Mind Medicine, SoundHound AI, or Canopy Growth?PR Newswire
- Stocks Set To Close Blowout Week, Month And Quarter At All-Time High; Gold Soars To Record [zero hedge]zero hedge
- Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD [Yahoo! Finance]Yahoo! Finance
AKBA
Earnings
- 3/14/24 - Beat
AKBA
Sec Filings
- 3/28/24 - Form 8-K
- 3/15/24 - Form 8-K
- 3/14/24 - Form 10-K
- AKBA's page on the SEC website